Novartis’ Zolgensma shows ‘continued benefit’ in SMA patients
66.7% of patients in the intent-to-treat population were able to feed orally without the need for feeding support
Read More
Tag: STR1VE-EU
- Asgard Therapeutics to present new preclinical data on AT‑108 at ASGCT 2026
- Theolytics announces first patient dosed in the Octopod‑IP trial
- UK medicines regulator grants marketing authorisation to Enflonsia for RSV prevention
- Saphnelo approved in the US for subcutaneous self‑administration
- Transgene completes randomisation in phase 2 trial of tg4050
